Taysha Gene Therapies Expands REVEAL Trial to Include Adolescent Rett Syndrome Patients

Written By Kathleen Otto

Taysha Gene Therapies, Inc., a clinical-stage gene therapy company specializing in AAV-based gene therapies for monogenic central nervous system (CNS) diseases, has received authorization from Health Canada for a protocol amendment in the ongoing REVEAL Phase 1/2 adult trial assessing TSHA-102. This amendment expands trial eligibility to include patients aged 12 and older diagnosed with Rett syndrome.

Kathleen Otto
Previous

Lantern Pharma's LP-284 Granted FDA Orphan Drug Designation for High-Grade B-cell Lymphoma Treatment
Next

NexPoint Capital Invests in Bioplastic Pioneer PlantSwitch's Early Growth Funding Round